128 related articles for article (PubMed ID: 21186793)
1. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
Caldwell JJ; Welsh EJ; Matijssen C; Anderson VE; Antoni L; Boxall K; Urban F; Hayes A; Raynaud FI; Rigoreau LJ; Raynham T; Aherne GW; Pearl LH; Oliver AW; Garrett MD; Collins I
J Med Chem; 2011 Jan; 54(2):580-90. PubMed ID: 21186793
[TBL] [Abstract][Full Text] [Related]
2. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles.
Arienti KL; Brunmark A; Axe FU; McClure K; Lee A; Blevitt J; Neff DK; Huang L; Crawford S; Pandit CR; Karlsson L; Breitenbucher JG
J Med Chem; 2005 Mar; 48(6):1873-85. PubMed ID: 15771432
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
Li HQ; Li DD; Lu X; Xu YY; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(1):317-23. PubMed ID: 22112541
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
8. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
[TBL] [Abstract][Full Text] [Related]
9. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.
Nguyen TN; Saleem RS; Luderer MJ; Hovde S; Henry RW; Tepe JJ
ACS Chem Biol; 2012 Jan; 7(1):172-84. PubMed ID: 22004065
[TBL] [Abstract][Full Text] [Related]
10. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
12. X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
FEBS Lett; 2011 Oct; 585(20):3245-9. PubMed ID: 21907711
[TBL] [Abstract][Full Text] [Related]
13. Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
Patel SD; Habeski WM; Cheng AC; de la Cruz E; Loh C; Kablaoui NM
Bioorg Med Chem Lett; 2009 Jun; 19(12):3339-43. PubMed ID: 19435660
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.
Foote KM; Mortlock AA; Heron NM; Jung FH; Hill GB; Pasquet G; Brady MC; Green S; Heaton SP; Kearney S; Keen NJ; Odedra R; Wedge SR; Wilkinson RW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1904-9. PubMed ID: 18294849
[TBL] [Abstract][Full Text] [Related]
15. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
[TBL] [Abstract][Full Text] [Related]
18. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
[TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors.
Long L; Wang YH; Zhuo JX; Tu ZC; Wu R; Yan M; Liu Q; Lu G
Eur J Med Chem; 2018 Sep; 157():1361-1375. PubMed ID: 30196060
[TBL] [Abstract][Full Text] [Related]
20. Strategies for the design of selective protein kinase inhibitors.
Sawa M
Mini Rev Med Chem; 2008 Oct; 8(12):1291-7. PubMed ID: 18855742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
